Emedgene is the world’s first completely automated genetic interpretation platform. We’re applying the most advanced AI technologies in order to dramatically scale genetic interpretation and discovery.

The Emedgene platform incorporates the AI Knowledge Graph, a knowledge base that aims to hold a current representation of the entire body of genomics knowledge, and is continuously updated with new information using NLP.  A set of custom machine learning algorithms regularly uncover clinically meaningful connection models within the AI knowledge graph. Using these algorithms, Emedgene can successfully pinpoint the causative mutations for both known and unknown genes.

Clinical labs using Emedgene improve dry lab efficiency, reducing time spent on interpretation and reporting, increasing yield and scaling their genomic interpretation operation.

Research organizations using Emedgene accelerate genomic-driven discovery through the application of end-to-end AI, from NLP of publications through custom machine learning algorithms.

Emedgene is used by some of the world’s leading genomic health labs.

Category: Healthcare IT
Sub-category: Decision Support System
Therapeutic Area(s): Neurology, Cardiology, Genetic Disorders, Pediatric
Company Status: Initial Revenues

To learn more about the company please visit their website: www.emedgene.com 

Emedgene will be visiting New Delhi and Jaipur end of this month as part of the Medical Delegation coming from Israel to India.

In Jaipur

Date: July 31st July 2018

Time: 13:00-17:00

Event: B2B Interaction (with Indian hospitals, Companies and distributors)

In New Delhi

Date: August 2nd 2018

Time: 10:30-14:00

Event: B2B Interaction (with Indian hospitals, Companies and distributors)

In order to meet them or know more about the activity please contact:

Mr. Tejinder Singh, Senior Trade Officer, New Delhi – tejinder.singh@israeltrade.gov.il